Cantor Fitzgerald Reaffirms Overweight Rating for Capricor Therapeutics (NASDAQ:CAPR)

Cantor Fitzgerald reissued their overweight rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report released on Thursday morning,Benzinga reports. They currently have a $30.00 price target on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Trading Down 10.4 %

NASDAQ CAPR opened at $12.86 on Thursday. The stock’s 50 day moving average is $14.06 and its two-hundred day moving average is $14.62. The company has a market capitalization of $584.74 million, a price-to-earnings ratio of -12.13 and a beta of 4.10. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. On average, analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after purchasing an additional 700,243 shares during the last quarter. Farallon Capital Management LLC bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $31,056,000. Geode Capital Management LLC raised its position in Capricor Therapeutics by 37.8% in the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after purchasing an additional 241,279 shares during the last quarter. Altium Capital Management LLC raised its position in Capricor Therapeutics by 150.5% in the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after purchasing an additional 429,000 shares during the last quarter. Finally, Woodline Partners LP bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $8,693,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.